Howard J. West

Oncology
4616 25th Ave NE
Seattle, WA 98105

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 138 publications

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

Journal: The Lancet. Oncology
Published: March 20, 2026

Squamous Non-Small Cell Lung Cancer: Current and Emerging Treatment Options.

Squamous Non-Small Cell Lung Cancer: Current and Emerging Treatment Options.

Journal: Clinical lung cancer
Published: May 01, 2025

Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer.

Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer.

Journal: ESMO open
Published: February 12, 2025

Cancer Care in the Era of Artificial Intelligence.

Cancer Care in the Era of Artificial Intelligence.

Journal: JAMA oncology
Published: March 28, 2024

Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer.

Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer.

Journal: Clinical lung cancer
Published: January 29, 2024

Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.

Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.

Journal: JAMA oncology
Published: December 28, 2023

ABIM Maintenance of Certification-Reply.

ABIM Maintenance of Certification-Reply.

Journal: JAMA
Published: December 19, 2023

Could We Have Improved on ADAURA? Refining Global Research Practices to Reduce Cancer Care Disparities.

Could We Have Improved on ADAURA? Refining Global Research Practices to Reduce Cancer Care Disparities.

Journal: JCO global oncology
Published: November 22, 2023

Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer.

Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer.

Journal: JAMA oncology
Published: November 16, 2023

Lessons from ADAURA: Can we improve on a positive trial?

Lessons from ADAURA: Can we improve on a positive trial?

Journal: Cancer
Published: November 14, 2023

Maintenance of Certification (MOC)-Benefit vs Burden.

Maintenance of Certification (MOC)-Benefit vs Burden.

Journal: JAMA
Published: September 22, 2023

Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting.

Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting.

Journal: Frontiers in oncology
Published: September 21, 2023
Showing 1-12 of 138

Last Updated: 09/26/2026